Jazz Pharmaceuticals earnings

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) reported record third-quarter revenue of $1.05 billion on Wednesday afternoon, up 14% year-over-year, propelled by strong sales of key therapies like Xywav, Epidiolex and Rylaze. The gross margin held steady at 89%. CEO Bruce Cozadd said Jazz remains "...

Jazz Pharmaceuticals plc (NASDAQ: JAZZ), a global biopharmaceutical company and manufacturer of Epidolex, announced its financial results late Tuesday for the full year and fourth quarter of 2021 and provided financial guidance for 2022. "2021 was a transformative year for Jazz,...

Jazz Pharmaceuticals plc (NASDAQ: JAZZ), a global biopharmaceutical company, announced its financial results Tuesday afternoon for the third quarter of 2021 and updated financial guidance for 2021. "Last year, we set the ambitious corporate objective of completing five key commercial...

Biopharmaceutical company Jazz Pharmaceuticals plc (NASDAQ: JAZZ) reported its financial results on Tuesday for the second quarter of 2021 with total revenue of $751.81 million, up by 34% from $562.43 million in the comparative period of 2020. Financial...